Search This Blog

Wednesday, December 18, 2019

Epizyme shares halted for today’s Ad Com review

Nasdaq has suspended trading in Epizyme (NASDAQ:EPZM) pending the release of news, in this case, the outcome of today’s FDA advisory committee meeting on its application for tazemetostat for epithelioid sarcoma.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)